Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX) will host a conference call on August 4, 2022, at 5:00 p.m. ET to report its second quarter 2022 financial results and discuss business highlights. Investors can join the call by dialing (888) 660-6390 domestically or (929) 203-1902 internationally, referencing conference ID 4855909. A live audio webcast will also be available on Aptinyx’s website, with a replay archived for 30 days. The company is developing therapies for brain and nervous system disorders, focusing on innovative NMDA receptor modulators.

Positive

• Aptinyx is in clinical development with three product candidates targeting significant indications including fibromyalgia and PTSD.
• The company has a proprietary platform generating a diverse pipeline of small-molecule NMDA receptor modulators.

Negative

• None.

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902 (international) and refer to conference ID 4855909. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, cognitive impairment, and post-traumatic stress disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005076/en/

Investor & Media Contact:

Patrick Flavin

Aptinyx Inc.

ir@aptinyx.com or corporate@aptinyx.com

847-871-0377

Source: Aptinyx Inc.

FAQ

When is Aptinyx's conference call for Q2 2022 results?

Aptinyx's conference call is scheduled for August 4, 2022, at 5:00 p.m. ET.

How can I access the Aptinyx conference call?

You can access the call by dialing (888) 660-6390 domestically or (929) 203-1902 internationally, using conference ID 4855909.

What is Aptinyx developing?

Aptinyx is developing therapies for brain and nervous system disorders, focusing on NMDA receptor modulators.

What are the key indications for Aptinyx's product candidates?

The key indications include fibromyalgia, cognitive impairment, and post-traumatic stress disorder.